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Abstract
Epidemiology and candidate gene studies indicate a shared genetic basis for celiac disease (CD) and rheumatoid arthritis
(RA), but the extent of this sharing has not been systematically explored. Previous studies demonstrate that 6 of the
established non-HLA CD and RA risk loci (out of 26 loci for each disease) are shared between both diseases. We
hypothesized that there are additional shared risk alleles and that combining genome-wide association study (GWAS) data
from each disease would increase power to identify these shared risk alleles. We performed a meta-analysis of two
published GWAS on CD (4,533 cases and 10,750 controls) and RA (5,539 cases and 17,231 controls). After genotyping the
top associated SNPs in 2,169 CD cases and 2,255 controls, and 2,845 RA cases and 4,944 controls, 8 additional SNPs
demonstrated P,5610
28 in a combined analysis of all 50,266 samples, including four SNPs that have not been previously
confirmed in either disease: rs10892279 near the DDX6 gene (Pcombined=1.2 610
212), rs864537 near CD247
(Pcombined=2.2 610
211), rs2298428 near UBE2L3 (Pcombined=2.5 610
210), and rs11203203 near UBASH3A (Pcombined
=1.1610
28). We also confirmed that 4 gene loci previously established in either CD or RA are associated with the other
autoimmune disease at combined P,5610
28 (SH2B3, 8q24, STAT4, and TRAF1-C5). From the 14 shared gene loci, 7 SNPs
showed a genome-wide significant effect on expression of one or more transcripts in the linkage disequilibrium (LD) block
around the SNP. These associations implicate antigen presentation and T-cell activation as a shared mechanism of disease
pathogenesis and underscore the utility of cross-disease meta-analysis for identification of genetic risk factors with
pleiotropic effects between two clinically distinct diseases.
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Introduction
Autoimmune disorders, including rheumatoid arthritis (RA) and
celiac disease (CD), affect about 5% of the population and have a
complex genetic background. Family-based epidemiology studies
suggest that there is a shared genetic basis between the two
autoimmune diseases [1]. Recent genome-wide association studies
(GWAS) have confirmed HLA and identified at least 26 other non-
HLA genetic loci with common alleles associated to each disease
(Table S1 and S2) [2,3]. The strongest genetic risk factor is the
HLA locus [2,3], where different alleles confer risk of the two
diseases. Six other risk loci outside of the HLA locus are shared
between CD and RA and include MMEL/TNFRSF14 [2,4], REL
[2,5,6], ICOS-CTLA4 [2,3,5,7], IL2-IL21 [2,3,8,9,10], TNFAIP3
[2,3,6,11], and TAGAP [2,3,8], (Chen et al, submitted) (Table 1
and Figure 1). These shared risk loci have emerged by simple
cross-comparison across published studies, rather than a rigorous
and systematic analysis of an integrated dataset. Because of the
nature of these reports, it is unknown whether the other CD and
RA risk alleles confer risk of both diseases. Moreover, it is
unknown whether there are additional shared risk alleles that have
not yet been discovered in any one disease.
A major challenge in identifying common alleles of modest
effect is the sample size required to have sufficient power to obtain
associations at a stringent level of statistical significance. Recent
studies of height [12], lipids [13] and body mass index [14] have
shown quite convincingly that very large sample sizes – more than
100,000 individuals – yield reproducible SNP associations for
common alleles of modest effect size. For diseases such as CD and
RA, which are relatively uncommon in the general population
(prevalence ,0.5–1% for each disease), similar sized cohorts are
difficult to ascertain. One solution to this problem is to combine
two phenotypes to search for pleiotropic risk alleles. So far this
approach has only been done for closely related phenotypes, such
as the Crohn’s disease and ulcerative colitis (together known as
inflammatory bowel disease (IBD)) [15], or for medical traits that
are known risk factors for disease (e.g., lipids and coronary artery
disease, obesity and type 2 diabetes) [13,16].
Another challenge is how to interpret statistical significance of
SNP associations in combined analysis of two clinically distinct
phenotypes. In a GWAS of common variants for a single pheno-
type, most consider P,5610
28 as statistically significant, as any
SNP at random from the genome has the same probability of being
associated with the phenotype and there are approximately 1
million uncorrelated common SNPs in the human genome [17].
However, this P-value threshold does not take into consideration
that (a) many common SNPs, not just a single SNP, are associated
with disease, and (b) the pleiotropy of risk alleles for related diseases
should, in theory, increase the prior probability that an allele is a
true-positive.In the case of autoimmunity,allelesoftencontributeto
riskof more than oneautoimmune disease [18].Accordingly,a SNP
with a confirmed association in one autoimmune disease has a
higher prior probability of being associated with another autoim-
mune disease. This principle has been used to declare that SNPs are
confirmed disease associations, if the SNP does not reach a stringent
level of significance (e.g., P,5610
28) in the other autoimmune
disease[7,19].Nonetheless,therearenoformalcriteriaforassigning
increased prior probabilities for SNPs across autoimmune diseases.
Table 1. Comparison of CD and RA risk alleles at seven shared risk loci.
Locus Locus name Top CD SNP Top RA SNP
LD between CD and
RA SNPs (D’ and r
2) Comment
1p36.3 MMEL1/TNFRSF14 rs3890745 [2] rs3748816 [3] 1 0.93 Same allele, same direction
2p16.1 REL rs13003464 [2] rs13031237 [5] 0.11 0.01 Different alleles
2q33.2 ICOS/CTLA4 rs4675374 [2] rs3087243 [3] 0.80 0.12 Incomplete LD
4q27 IL2/IL21 rs13151961 [2] rs6822844 [10] [3] 1 0.90 Same allele, same direction
6p21 HLA rs2187668 (DQA1*0501-DQB1*0201 tag) [2] rs6910071 (DRB1*0401 tag) [3] 1 0.04 Different alleles
6q23.3 TNFAIP3 rs2327832 [2] rs6920220 [3] 1 1 Same allele, same direction
6q25.3 TAGAP rs1738074 [2] rs212389 (Chen et al, submitted) 0.56 0.27 Different alleles
Columns Top SNP CD and Top SNP RA – best reported SNP in the locus, as indicated in the reference paper. Association is indicated to the same allele if the r
2 between
CD and RA SNP is above 0.9.
doi:10.1371/journal.pgen.1002004.t001
Meta-Analysis of CD and RA
PLoS Genetics | www.plosgenetics.org 2 February 2011 | Volume 7 | Issue 2 | e1002004In the current study, we hypothesized that there are additional
alleles that influence risk of both CD and RA in a pleiotropic
manner. To increase power to detect these alleles, we combined
two previously published GWAS of each disease, followed by
replication in both CD and RA. We use our GWAS data to arrive
at an empirical threshold for declaring SNPs as shared risk alleles
for the two diseases. In doing so, we identified fourteen shared
CD-RA risk alleles, which point to T-cell receptor signaling as a
key shared pathway of disease pathogenesis.
Results
Comparing known risk alleles across diseases
We first aimed to investigate the status of established CD and
RA loci across these two diseases using genotype data from
published GWAS datasets of CD (4,533 cases, 10,750 controls) [2]
and RA (5,539 autoantibody positive RA cases and 17,231
controls) [3] (See Materials and Methods for description of both
cohorts). We considered only those reported loci with at least
one risk allele associated at P,5610
28 with confirmation in
independent samples. There are 26 non-HLA loci from each
disease that satisfy this stringent criterion, representing 46 distinct
risk loci (Tables S1 and S2). We investigated the association of the
26 non-HLA CD SNPs in RA, and the 26 non-HLA RA SNPs in
CD. Figure 1A and 1B show the OR and 95% CI of the 52 SNPs
and the association statistics within the two diseases. Of the 26 CD
SNPs, 11 are associated with risk of RA at P,0.05 (Table S1).
Similarly, from 26 RA SNPs, 9 are associated with risk of CD at
P,0.05 (Table S2). After excluding the six loci established in both
diseases, this distribution remains non-random (P,2610
24,
Fisher’s test), indicating additional sharing of risk loci between
the two diseases.
Comparing distribution of putative risk alleles across
diseases
To provide additional evidence that there are shared risk alleles,
we analyzed the distribution of moderately associated SNPs from
the GWAS datasets (i.e., putative risk alleles) across the two
autoimmune diseases. We investigated whether the subset of SNPs
associated with CD at P,0.001 in the CD-GWAS are randomly
distributed in the RA GWAS results, and vice-versa. After
removing the established CD and RA risk loci, we performed
association analysis on a set of independent SNPs for each disease.
In CD, 70,520 SNPs remained after pruning SNPs in linkage
disequilibrium (LD) (see Materials and Methods for details), of
which 342 were associated with CD at P,0.001. In RA, 70,812
SNPs remained after LD-pruning, of which 282 were associated
with RA at P,0.001. Using Fisher’s test, we observed a non-
random distribution of association with CD in the subset of
P,0.001 RA GWAS SNPs, as well as a non-random distribution
of association with RA in the subset of P,0.001 CD GWAS SNPs
(P,5610
25 for both diseases; see Figure 2 and Table S3A).
Similar results were obtained when we used the Wilcoxon rank
sum and Kolmogorov-Smirnov tests to analyze the distributions of
SNP associations across diseases (Table S3B). From this analysis,
we conclude that a SNP associated with risk of CD at P,0.001 has
an increased prior probability of being associated with RA, and a
SNP associated with risk of RA at P,0.001 has an increased prior
probability of being associated with CD.
GWAS and replication—same allele, same direction
While the analyses described above indicate that additional
shared risk alleles remain to be discovered, these analyses do not
identify which specific SNPs influence risk of both disease. To
identify new shared risk alleles, we performed an inverse variance
weighted meta-analysis [20] in which we assumed that the same
allele confers risk of both diseases. A total of 472,854 SNPs outside
the HLA (Chr6: 20–40 MB) overlapped between the two GWAS
datasets and were included in the meta-analysis. We did not
exclude the established CD and RA loci outside of the HLA region
from the meta-analysis, as we considered the possibility that there
may be novel risk alleles within these loci. The Q-Q plot of
CD+RA meta-anlaysis P-values (Pcombined) shows an enrichment
of non-HLA associated SNPs in the tail of the distribution
(Figure 3A), with no evidence for systematic bias across all SNPs
(lGC=1.011). A similar result was obtained after excluding known
associated loci for both diseases (Figure 3A). The Manhattan plot
indicates loci where significance increased in the combined cohort
(Figure S1).
Sixty-five SNPs from 21 distinct genomic regions were
associated with both CD and RA in the combined analysis with
Pcombined,1610
25, and with disease-specific P,0.01 (Tables S4
and S5). Of these 21 loci, five are established in both diseases
(TNFAIP3, CTLA4/ICOS, IL2/IL21, REL and MMEL1/
TNFRSF14); five are established CD loci (SH2B3, PTPN2,
8q24.2, SOCS1, ICOSLG); and four are established RA loci
(ANKRD55, STAT4, TRAF1/C5 and PRKCQ). The remaining 7
have not been previously confirmed in either disease (Table 2,
Table S5).
To determine which of these loci are associated with both
diseases – particularly those 7 loci not previously implicated in
either disease and 9 loci established as risk alleles in either CD or
RA alone – we selected from each of these 16 loci one most
associated SNP for replication in additional 2,169 CD cases and
2,255 controls, and 2,845 autoantibody positive RA cases and
4,944 controls (see Materials and Methods for sample informa-
tion). Five out of 16 SNPs were previously genotyped in samples
Author Summary
Celiac disease (CD) and rheumatoid arthritis (RA) are two
autoimmune diseases characterized by distinct clinical
features but increased co-occurrence in families and
individuals. Genome-wide association studies (GWAS)
performed in CD and RA have identified the HLA region
and 26 non-HLA genetic risk loci in each disease. Of the 26
CD and 26 RA risk loci, previous studies have shown that
six are shared between the two diseases. In this study we
aimed to identify additional shared risk alleles and, in
doing so, gain more insight into shared disease patho-
genesis. We first empirically investigated the distribution
of putative risk alleles from GWAS across both diseases
(after removing known risk loci for both diseases). We
found that CD risk alleles are non-randomly distributed in
the RA GWAS (and vice versa), indicating that CD risk
alleles have an increased prior probability of being
associated with RA (and vice versa). Next, we performed
a GWAS meta-analysis to search for shared risk alleles by
combing the RA and CD GWAS, performing both
directional and opposite allelic effect analyses, followed
by replication testing in independent case-control datasets
in both diseases. In addition to the already established six
non-HLA shared risk loci, we observed statistically robust
associations at eight SNPs, thereby increasing the number
of shared non-HLA risk loci to fourteen. Finally, we used
gene expression studies and pathway analysis tools to
identify the plausible candidate genes in the fourteen
associated loci. We observed remarkable overrepresenta-
tion of T-cell signaling molecules among the shared genes.
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PLoS Genetics | www.plosgenetics.org 3 February 2011 | Volume 7 | Issue 2 | e1002004Figure 1. Established CD and RA SNPs and their association across diseases. (A) Known CD SNPs in RA. The figure represents OR and CI for
the established CD SNPs (p,5610
28, one SNP per locus) in RA meta-analysis (5,539 auto-anbitody positive cases and 17,231 controls). (B) Known RA
SNPs in CD. The figure represents OR and CI for the established RA SNPs (p,5610
28, one SNP per locus) in CD meta-analysis (4,533 cases and 10,750
controls). For the six shared loci established in both diseases, figure 1A includes the top CD SNP and figure 1B the top RA SNP. From six shared loci,
three (TNFRSF14, IL2/IL21 and TNFAIP3) are associated with same SNP or a good proxy (r
2.0.9) in both diseases; in other three loci – CTLA4, REL and
TAGAP – the most associated SNPs in CD and RA are not in strong LD with each other (r
2,0.3), which is reflected in moderate association (CTLA4)o r
no association (REL) of these SNPs in the second disease. The TAGAP SNPs show association to opposite alleles in CD and RA.
doi:10.1371/journal.pgen.1002004.g001
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PLoS Genetics | www.plosgenetics.org 4 February 2011 | Volume 7 | Issue 2 | e1002004that overlapped with our replication samples [2,3], and are
included here for completeness. Two SNPs – rs7283760 in the
CD-established ICOSLG locus and rs2181622 in the RA-
established PRKCQ locus – were not genotyped in the replication
samples for technical reasons. We did not attempt replication of
SNPs from the five established loci associated with risk of both CD
and RA. We conducted association tests of the 14 SNPs in the
replication and combined cohorts with inverse variance weighted
meta-analysis, where we analyzed CD-only samples [replication
(PCD-repl) and GWAS+replication (PCD)], RA-only samples [rep-
lication (PRA-repl) and GWAS+replication (PRA)], and RA+CD
samples [all GWAS+replication samples together (Poverall)].
As shown in Table 2, of the 4 established CD risk SNPs, two
replicated in the RA samples with PRA-repl,0.05 and obtained
PRA,0.001 in all available RA case-control samples (SH2B3
(12q24.1) and an intergenic region on 8q24.2, PRA=1.5610
25
and 9.1610
25 respectively). Similarly, of the 3 established RA risk
SNPs tested in our study, two replicated in the CD samples with
PCD-rep,0.05 and obtained PCD,0.001 in all available CD case-
control samples (STAT4 (2q32.3) and TRAF1-C5 (9q33.2),
PCD=9.7610
24 and 9.3610
24 respectively). All four of these
SNPs have Poverall,5610
28 in analysis of all 50,266 CD and RA
samples.
Of the 7 SNPs not previously established as genome-wide
significant in either CD or RA, four were significantly replicated in
both diseases at PCD-repl,0.05 and PRA-repl,0.05, were associated
to each disease with PCD,0.001 and PRA,0.001 and achieved
Poverall,5610
28 in the combined CD-RA cohort (CD247 (1q24.2),
UBE2L3 (22q11.2), DDX6 (11q23.3) and UBASH3A (21q22.3); see
Table 2). The strongest signal in the combined analysis was
observed from the DDX6 locus (rs10892279, Poverall=1.2610
212).
This SNP achieved genome-wide significance PRA=1.1610
28
in the RA cohort alone, and PCD=2.0610
25 in the CD cohort.
SNPs near CD247 and UBE2L3 were previously suggestively
associated in both CD and RA [2,3]. The replication data
presented here, together with the combined analysis of Poverall,
5610
28, demonstrate that these SNPs are indeed true positive
associations for CD and RA. Of note, SNPs in the UBE2L3 are also
associated with risk of systemic lupus erythematosus [21] and
Crohn’s disease [22], and the CD247 locus is associated with
systemic sclerosis [23].
Figure 2. QQ plot of CD associated SNPs in RA and RA
associated SNPs in CD. QQ plot of CD associated SNPs (p,0.001) in
RA (green) and RA associated SNPs (p,0.001) in CD (black). The most
strongly associated SNPs (after removing known risk loci) in one disease
were further filtered for P,0.001, and the resulting LD-pruned SNP sets
were then tested for their distribution of association in the other
disease. The QQ-plots indicate excess sharing of moderately associated
SNPs across CD and RA.
doi:10.1371/journal.pgen.1002004.g002
Figure 3. QQ plot of CD-RA meta-analysis by directional method and opposite allelic effect. CD-RA inverse variance weighted meta-
analysis assuming allelic effects in the same direction in the two diseases (panel A) and opposite allelic effects (panel B). Black – all loci except the
MHC region (chr. 6: 20–40 Mb). Green – all loci except MHC and established CD and RA regions (1 MB around previously validated SNPs excluded).
doi:10.1371/journal.pgen.1002004.g003
Meta-Analysis of CD and RA
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There is increasing evidence that alleles conferring risk of one
autoimmune disease confer protection to another autoimmune
disease [3,7,8,24,25,26]. We therefore performed an analysis of
alleles that conferred risk in either CD or RA, but protection in the
other disease (Figure 3B), followed by independent testing in our
replication cohort. Nine loci were identified using the same criteria
as above (Pcombined,1610
25, and disease-specific P,0.01; see
Tables S6 and S7). The strongest shared signal from this analysis
was at the TAGAP locus (6q25.3, rs212388 Pcombined=5.4610
212),
an established risk locus in both CD and RA [2,3,8] (Chen, et al,
submitted). Another locus that had an apparent opposite allelic
effect was REL (2p16.1), although it shows a more complex pattern
of association. From the three SNPs in the REL locus that were
associated to both diseases with Pcombined,1610
25, and disease-
specific P,0.01, two SNPs showed similar direction of association
with CD and RA, whereas one SNP showed opposite direction-
ality of association (Tables S4 and Table S6). Of the remaining
SNPs, no single SNP replicated in both diseases at P,0.05 and
achieved P,5610
28 in an overall analysis of all data. We
observed a trend of an association at the chromosome 2p23.1
(near the LBH gene) locus (rs7579944, PCD=9.7610
26 and
PRA=2.3610
24 in the CD and RA cohorts, respectively;
Poverall=1.1610
28 in the combined analysis, but no formal
replication in RA cohort (PRA-repl =0.13)) (Table 3). Although
these data strongly suggest that chromosome 2p23.1 is a shared
CD-RA risk locus, additional replication will be required.
Selecting most likely causal gene near associated SNP
We used two methods to identify the most likely causal gene in
the region of the 14 shared non-HLA risk loci. First, we used a
computational algorithm, GRAIL, which systematically searches
for gene relationships across risk loci using PubMed abstracts [27].
In total, 14 shared loci contain 51 genes; 16 of these scored P,0.1
by GRAIL (Table S8). Second, we analyzed each shared SNP for
evidence of cis-acting gene expression in peripheral blood cells
derived from 1,469 individuals (Fehrmann et al, submitted). From
14 shared SNPs, 7 showed a significant (genome-wide FDR
corrected ,0.05) effect on expression of one or more transcripts in
the LD block around the SNP (Table S9, Figure S2A-S2P). It is
interesting to note that of the four novel SNP associations
identified from this study, three show convincing effects on the
expression of nearby genes, in particular rs864537-CD247
(P=3.5610
211), rs2298428-UBE2L3 (P=2.0610
299) and
rs11203203-UBASH3A (P=8.7610
210) (Table S9, Figure S2).
Based on these two methods, 23 genes located in the 14 shared loci
were selected as plausible candidates for shared CD-RA
pathogenesis (Table 4 and Table S10).
Discussion
In this study we demonstrate that there are 14 loci that
contribute to risk of both RA and CD: 6 previously established risk
loci and 8 loci identified in our study. Of the 8 new loci, 4 had not
been associated previously with either disease at genome-wide
significance (CD247, UBE2L3, DDX6, and UBASH3A) and 4 had
been established in one but not the other autoimmune disease
(SH2B3, 8q24.2, STAT4, and TRAF1-C5). Our study represents the
first systematic effort to compare the genetic basis of CD and RA
in a very large sample set – more than 50,000 combined case-
control samples – to identify risk alleles with pleiotropic effects on
two clinically distinct autoimmune diseases.
To identify the shared risk loci, we performed two types of
analyses. First, we compared the distribution of established and
putative risk alleles across both autoimmune diseases. Both
distributions were non-random, providing empirical evidence that
the genetic basis of the two autoimmune diseases overlaps. Second,
we combined GWAS data and performed independent replication
to search for specific SNPs associated with both diseases. We
performed the GWAS meta-analysis under a genetic model in
which the same allele conferred risk of both autoimmune diseases,
as well as a model in which the same allele conferred risk to one
disease and protection from the other disease. Of the newly
identified 8 shared risk alleles, all 8 confer same risk direction on
both CD and RA.
Our study represents one of the first GWAS meta-analysis of
clinically distinct but epidemiologically related diseases. This
approach has appeal for diseases in which there is thought to
be a shared genetic basis, as it adds power to detect alleles of
modest effect size. A GWAS meta-analysis has been conducted
on early onset inflammatory bowel disease (IBD), which include
Crohn’s disease (CrD) and ulcerative colitis (UC) [15]. CrD and
UC are clinically similar diseases both affecting bowel, and often
can not be distinguished between each other (presented as
undifferentiated IBD), especially in children. In contrast to the
IBD study, our GWAS meta-analysis combined phenotypes with
different clinical presentations (enteropathy and inflammatory
arthritis).
In combining GWAS data across clinically distinct phenotypes,
an important question is how to interpret statistical significance
and therefore how to declare a SNP as a confirmed association for
each disease. In our study, we empirically demonstrated that SNPs
associated with risk of either CD or RA have a higher probability
of being associated with the other autoimmune – even if the SNP is
not yet a confirmed association in either disease (Figure 2). We
observed that a SNP associated with risk of CD at P,0.001 has an
increased prior probability of being associated with RA, and a
SNP associated with risk of RA at P,0.001 has an increased prior
probability of being associated with CD. Based upon these
analyses, we propose objective criteria for declaring a SNP as a
shared CD – RA risk SNP in our study: it must achieve
Poverall,5610
28 in combined analysis of CD&RA, with the
additional requirement of P,0.05 in an independent replication
dataset and P,0.001 for each disease. Applying these criteria to
our meta-analysis results we conclude that there are 14 non-HLA
shared CD and RA risk loci (Table 1 and Table 2).
We applied two methods to select the most likely causal gene in
the region of the 14 shared non-HLA risk loci, and in doing so
gain insight into shared RA-CD pathogenesis: (1) a computational
algorithm, GRAIL, which systematically searches for gene
relationships across risk loci using PubMed abstracts [27] and (2)
a dataset of cis-acting gene expression in peripheral blood cells
derived from 1,469 individuals [27] (Fehrmann et al, submitted).
Using these methods we prioritized 23 genes located in the 14
shared loci as plausible functional candidates. Interestingly, two
out of four novel loci function in T-cell activation/signalling:
CD247, which encodes for the zeta chain of the T-cell receptor-
CD3 complex, and UBASH3A, which is a suppressor of T-cell
receptor signaling, underscoring antigen presentation to T-cells as
a critical shared mechanism of disease pathogenesis [28,29]. This
observation is consistent with the known functions of several of the
other shared RA-CD risk loci which were highlighted in GRAIL
and expression analysis (CTLA4, ICOS, TAGAP, SH2B3, and
STAT4). These genes are known to modulate T-cell activation
and/or differentiation: CTLA4 is a negative regulator of T-cell
activation [30], ICOS is a T-cell co-stimulator molecule [31],
TAGAP is up-regulated upon T-cell activation[32], SH2B3 (LNK) is
an adaptor protein involved in T-cell activation [33], and STAT4
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cells [34].
How might these 14 loci influence risk of two clinically distinct
autoimmune diseases? MHC class II alleles, the strongest risk
factor in both diseases, are notably different between the two
diseases: HLA-DQ*A1 and *B1 alleles in CD and HLA-DRB1
‘‘shared epitope’’ alleles in RA. Under a model in which MHC
class II molecules confer risk by preferentially presenting disease-
specific antigens (gluten in CD, most likely citrullinated antigens in
RA) to autoreactive T-cells, then disease specificity is determined
in large part by the inheritance of specific HLA alleles and
exposure to disease-specific antigens. Our genetic data extends this
model to implicate downstream signaling events common to both
diseases that may lead to altered T-cell activation and differen-
tiation. Whether abnormal T-cell signaling occurs in the thymus
(where autoreactive T-cells undergo negative selection), in the
peripheral circulation (where autoreactive T-cells exert their
effects), or in another manner remains to be determined.
There are several limitations of our study. First, we did not
search for loci in which an allele contributes to risk of one
autoimmune disease and an independent allele contributes to risk
of the other autoimmune disease. The REL locus provides an
example in which the risk alleles for the two autoimmune diseases
appear distinct [2,5,6]. Second, our study is underpowered to
detect shared risk alleles of more modest effect size, despite a
combined sample size of .50,000 case-control samples. As more
samples and SNPs are genotyped between these diseases,
additional risk alleles will be discovered. Third, we did not
attempt to fine-map the 26 established risk loci for both
autoimmune diseases to determine if a single allele is responsible
for risk in both autoimmune diseases. And fourth, we made no
attempt to search for low-frequency or rare variants that are
shared between RA and CD. Implementation of newer sequencing
technologies will be required to search for rare risk variants.
In summary, our study adds four novel loci to established RA
and CD risk loci (CD247, UBE2L3, DDX6, and UBASH3A). It also
adds four loci previously established in one or the other disease to
the list of shared CD-RA risk loci (SH2B3, 8q24.2, STAT4, and
TRAF1-C5). With six previously established CD-RA risk loci, there
are now 14 shared CD-RA risk loci, out of 50 established loci for
either of the two autoimmune diseases. We emphasize that these
are conservative estimates of shared risk loci between the two
diseases, as our study may be underpowered to detect common
alleles of modest effect size, and we have not considered genetic
models in which different alleles within one locus contribute to risk
of the two diseases. In addition to the HLA associations, these
shared risk loci clearly point to the critical role of antigen
presentation via MHC class II molecules to the T-cell receptor,
and subsequent activation and differentiation of T-cells in shared
disease pathogenesis.
Materials and Methods
Ethics statement
Institutional review boards at each collection site approved the
study, and all individuals gave their informed consent.
Sample collection
CD GWAS dataset. CD case-control GWA study included
15,283 individuals (4533 cases, 10750 controls) from 5
populations: Finnish (FIN) (674 cases, 647 controls), Italian (IT)
(541 cases, 497 controls), Dutch (NL, 876 cases, 803 controls), and
two collections from UK population, UK1 (737 cases, 2596
controls) and UK3 (1922 cases, 1849 controls) (described in details
in[2]).The genotyping of all cohorts except UK1 cases was done
on Illumina platforms including 550K SNPs (either Illumina
Hap550, or Illumina 610 or 670 Quad, or Illumina 1.2 M). The
genotyping of UK1 cases (n=737) was done on Illumina 317K
arrays. The subset of SNPs successfully genotyped on Illumina 550
and Quadr platforms, but not on Hap300 platform (n=196860)
was further imputed in the UK1 dataset, using Plink and HapMap
Phase 2 European CEU founders as a reference panel [35].
RA GWAS dataset. The RA meta-analysis includes 5,539
autoantibody positive RA cases and 17,231 controls of European
ancestry as described previously [3]. This study comprises six
GWAS case-control collections, genotyped on various platforms.
The imputation was conducted on GWAS genotype data for each
GWAS collection separately, using the IMPUTE software [36]
and haplotype-phased HapMap Phase 2 European CEU founders
as a reference panel. In total, 2.56 million SNPs were imputed.
Identity by state (IBS) analysis was run on controls from both CD
and RA GWAS datasets. The overlapping controls genotyped in
both CD and RA datasets were excluded from the RA analysis.
Replication cohorts. The replication cohorts included 2,169
CD cases and 2,255 controls, and 2,845 antibody-positive RA
cases and 4,944 controls. The CD replication cohorts included
three case-control collections from Ireland, Italy and Poland; all
collections were geographically matched and are described
previously [2]. The five RA replication collections included (1)
CCP or RF positive Dutch cases from Groningen and Nijmegen,
together with geographically matched controls (Replication cohort
1, R1); (2) CCP positive white individuals from North America
(Replication cohort 2, R2; this collection is called i2b2); (3) North
American RF positive cases and controls matched on gender,
age, and grandparental country of origin from the Genomics
Collaborative Initiative (GCI, Replication cohort 3, R3); (4) CCP
or RF positive Dutch cases and controls from Leiden University
Medical Center (LUMC; Replication cohort 4, R4); and (5) CCP
positive cases drawn from North American clinics and controls
from the New York Cancer Project (together this collection is
called NARAC-II), matched on ancestry informative markers data
(Replication cohort 5, R5). All cohorts except i2b2 were described
in detail in [3], whereas i2b2 is described in [37]. Summary
information on these samples is presented in Table S11.
Genotyping
Replication analysis of 15 SNPs was performed on the Sequenom
iPlex platforminthree centers– (1)Broad institute (allCD cases and
controls, and RA replication cohorts R1 and R2); (2) Celera
Diagnostics (Alameda California, USA; RA replication cohort R3
and R4); and (3) National Institute of Arthritis and Musculoskeletal
and Skin Diseases (NIAMS, RA replication cohort R5). (See Table
S11 for details). If the SNPs could not be designed into the iPLEX
pool, then a proxy SNP was included. Information on the iPLEX
design, proxies and cohorts genotyped in different centers is
presented in Tables S11 and S12. We excluded SNPs in each
replication collection if they were missing .10% genotype data,
,1%MAFandPHWE,10
23.For5 outofthe20SNPs that satisfied
the replication criteria in either the directional or opposite allelic
effect analysis, replication results were already available for CD and
RA samples from the studies Dubois et al [2] and Stahl et al[3],
respectively. For these 5 SNPs, we included genotype data from all
replication samples available in these studies.
Data analysis
GWAS meta-analysis. The meta-analysis of CD and RA
datasets was performed using an inverse variance-weighted
method. Analysis was performed in R package as described
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directions, two tests were performed. First, the directional meta-
analysis was done; second, the direction of association was flipped
in RA dataset and an opposite-allelic effect analysis was
performed. In total, 477,662 SNPs either directly genotyped on
the Illumina Hap550 platform, or genotyped on Hap300 and
imputed in UK1 cases were included in the analysis; all SNPs
overlapped with genotype or imputed SNPs from the RA dataset.
In both diseases the genomic control corrected results were used
for the meta-analysis.
Replication analysis. Replication and combined analyses
were done with an inverse variance-weighted method. Combined
(GWAS + replication) analysis within one disease (CD or RA) was
done with a directional method. Replication association tests were
one-tailed, for the same allele being risk or protective as in the
GWAS meta-analysis. Combined analysis of all CD and RA
samples was done for the same (directional or opposite) allelic
effect as was estimated in GWAS meta-analysis.
Distribution of risk alleles in GWAS. For the analysis of
distribution of risk alleles, we excluded SNPs located within 1 MB
around each of the most associated SNPs (26 in each disease); for
the MHC and PTPN22 loci, we excluded 20 Mb and 2 Mb,
respectively (chr. 6: 20–40 Mb and chr. 1: 113–115 Mb). The
pruning of SNPs in linkage disequilibrium (LD) was done by
selecting SNPs to retain and then removing all SNPs with r
2.0.1
in the HapMap2 reference panel. Pairwise LD tables were
generated from the HapMap2 release 24 phased haplotype data
distributed with the IMPUTE software; r
2 values were calculated
for all SNPs within 1 Mb of each other. For a given analysis, the
most strongly associated SNPs (after removing 1 Mb around
known associated SNPs) in one disease were retained. We also
filtered for SNPs with P,0.001. The resulting LD-pruned SNP
sets were then tested for non-random distributions of association
in the other disease. Fisher’s rule for combining P-values
({2
Pn
i~1 ln(Pi)~ x x2
2n)( 22 gln(P) ,x
2
2n) was used to test the null
hypothesis of a uniform distribution of P-values for association
with a given disease. Kolmogorov-Smirnov and Wilcoxon rank
sum tests were performed to test for overall difference and
difference in location, respectively, of the distributions of P-values
in a given disease, for SNPs with P,0.001 versus P$0.001 in the
other disease. One-sided tests were conducted, with the alternative
hypothesis that SNPs associated with one disease would also show
evidence of association with the other.
Gene expression. The analysis of gene expression was done
on PBMC of 1,469 individuals, as previously described [2]. In this
dataset, we included SNPs with genotyping call-rate $95%,
Hardy-Weinberg P-value $0.001, and MAF $5%. Expression
data was quantile normalized, centered to the mean and scaled
such that all probes had a standard deviation of 1. Principal
component analysis was performed over the sample correlation
matrix, in order to capture non-genetic variation. The variation
described within the first 50 principal components was sub-
sequently subtracted from the expression data as described by
Fehrmann et al (Fehrmann et al, submitted). Effects were deemed
cis-effects, when the mid-probe to SNP distance was #250 kb.
False discovery rate was controlled at 5%, by comparing observed
p-values with p-values obtained after permuting sample labels 100
times. The Fehrmann et al manuscript specifically investigated
whether SNPs in the Illumina probe sets might explain the eQTL
results: eQTL associated SNPs were checked for LD with SNPs
from 1000 genomes pilot data located within probe sequences.
Specifically for our study, we verified that none of the eQTL
associated SNPs was in high LD (r
2.0.1) with any of the 1000
genome SNPs located within Illumina probe sequences.
Supporting Information
Figure S1 Manhattan plots for GWAS analysis. Manhattan plot
for GWAS in CD (A), RA (B), CD-RA with directional meta-
analysis (C) and CD-RA with opposite allelic effect (D). Figure E is a
combined picture of the four analyses. Yellow – CD; blue – RA;
green – CD-RA directional; purple – CD-RA opposite allele. In
figure E, the 14 shared CD-RA loci are annotated. The HLA locus
(chr6: 20–40 MB) is excluded from the analysis. In RA, three SNPs
in PTPN22 locus are associated at p,10-24 and therefore are
excluded from the plot for the purpose of scale. The PTPN22 SNPs
excluded from RA plot are: rs2476601 P(RA)=3.6610
268,
rs2358994 P(RA)=8.2610
231, and rs1230661 P(RA)=6.1610
225.
(PDF)
Figure S2 Cis eQTL genotype – expression correlation analyses
in associated SNPs. Individual level gene expression data (residual
variance after Transcriptional Components removed) from 1469
PAXgene samples. Spearman Rank Correlation coefficients and P
values are shown for HT-12 and Ref. 8 data and for meta-analysis
results. Right Y axis, average expression rank, is a measure of how
strongly the tested probe is expressed amongst all probes in the
dataset. Unannotated probes are manually plotted and localized to
the following transcripts: Probe 2810202 – PHF19, Probe 6980470
– TMPRSS3, Probe 1230242 – UBE2L3.
(PDF)
Table S1 Established CD SNPs and their association to RA.
Candidate genes in the blocks are mentioned. Top P-value in CD is
indicated as in the reference paper [2]. CD_P column indicates the
p-value in CD-GWAS dataset (4,533 cases and 10,750 controls);
RA_P column indicates the p-value in RA-GWAS dataset (5,539
cases and 17,231 controls). OR is given for the minor allele.
(DOC)
Table S2 Established RA SNPs and their association to CD.
Candidate genes in the blocks are mentioned. Top P-value in RA is
indicated as in the reference papers [3,4,5,10,11,39,40,41,42,43].
CD_P column indicates the p-value in CD-GWAS dataset; RA_P
column indicates the p-value in RA-GWAS dataset; OR is given for
the minor allele. The CD results for RA SNPs that were not
genotyped in CD GWAS (not present on Illumina Hap550
genotyping array), are either imputed or estimated from the best
genotyped proxy SNP (indicated in column ‘‘genotyped/imputed’’).
When proxies wereused,ther
2 with RA SNP is indicatedincolumn
‘r
2 for proxy’. For imputed SNPs the imputation score is annotated
in column ‘Imp. score’. * - the perfect proxy rs13017599 was
genotyped in the reference paper. + - the association in TNFRSF14
does not reach P,5610
28, however this locus was included as RA-
established locus as it was implicated in several independent studies
[3,39,41].
(DOC)
Table S3 Distribution of CD associated SNPs (P,0.001) in RA
dataset and RA associated SNPs (P,0.001) in CD datasets. 3a.
Goodness of fit tests of no association, using Fisher’s Rule for
combining P-values. 3b Results of Kolmogorov-Smirnov and
Wilcoxon rank sum tests for non-random distribution of associated
SNPs across diseases. N – number of SNPs associated to CD and
RA at p,0.001 after LD-pruning. Df – degrees of freedom.
(DOC)
Table S4 SNPs associated to CD-RA with P,1610-5 and CD
and RA with P,0.01; directional analysis. The table includes all
SNPs associated to CD-RA in directional GWAS meta-analysis
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per diseases P,0.01 (columns ‘CD_P’ and ‘RA_P’). OR is given
for the reference (minor) allele.
(DOC)
Table S5 CD-RA meta-analysis results, directional analysis –
one top SNP per loci. One most associated SNP per locus is
indicated. OR is given for the reference (minor) allele. Cut-off for
the P-values is the same as in Table S4. SNPs are sorted for the P-
value in CDRA meta-analysis. Loci established in both diseases
are indicated in bold.
(DOC)
Table S6 SNPs associated to CD-RA with P,1610-5 and CD and
RA with P,0.01; analysis of opposite allelic effect. The table includes
all SNPs associated to CD-RA in GWAS meta-analysis of opposite
alleleic effect with P(combined) P,1610-5 (column ‘CD-RA_P_opp’)
and P-value per diseases P,0.01 (columns CD_P and RA_P).
(DOC)
Table S7 CDRA meta-analysis results, opposite allelic effect –
one top SNP per loci. One most associated SNP per locus is
indicated. OR is given for the reference (minor) allele. Cut-off for
the P-values is the same as in Table S6. SNPs are sorted for the P-
value in CD-RA meta-analysis. Loci established in both diseases
are indicated in bold.
(DOC)
Table S8 GRAIL analysis of associated loci. The P-value for
each candidate gene is based on the number of relationships to
other associated genes listed in the third column. GRAIL is
available at http://www.broadinstitute.org/mpg/grail/.
(DOC)
Table S9 Shared CD-RA risk variants correlated with cis gene
expression. ‘HT-12’ comprise 1240 individuals with blood gene
expression assayed using Illumina Human HT-12v3 arrays, ‘Ref-
8v2’ comprise 229 individuals with blood gene expression assayed
using Illumina Human-Ref-8v2 arrays.
ASpearman rank correla-
tion of genotype and residual variance in transcript expression.
Meta-analysis eQTL P value shown if both datasets had identical
probes. See Figure S2 for detailed results and Materials and
Methods for sample information and references.
(DOC)
Table S10 Characteristics of 23 candidate genes in shared loci.
(DOC)
Table S11 Information on replication cohorts. Case-control
collections included to the replication step in CD (top panel) and
RA (bottom panel). For each collection, we list the source of
controls, geographic origin, autoantibody status of RA cases,
numbers of cases and controls, genotyping platform and
genotyping center, and the strategy used to correct for case-
control population stratification. See Materials and Methods for
additional details. NIAMS – National Institute of Arthritis and
Musculoskeletal and Skin Diseases.
(DOC)
Table S12 Information on proxies used in three iPLEX pools.
R
2 -r
2 between GWAS and SNP pools used in replication step
(HapMapCEU,ascalculatedinSNAP(http://www.broadinstitute.
org/mpg/snap/)). A – iPLEX pool used in Broad institute (BI) was
used to genotype all replication cohorts for celiac disease and
replication cohorts R1 and R2 in rheumatoid arthritis, as indicated
in Table S11.
(DOC)
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